neuroClues

neuroClues is a Belgian MedTech company that has developed a CE-marked medical device for the quantitative analysis of eye movements as neurological biomarkers. The technology rests on a well-established body of neurological research: anomalies in saccadic eye movements — their speed, precision, and latency — are early and objective indicators of a range of neurological conditions, from Parkinson's disease and Alzheimer's to the after-effects of stroke and multiple sclerosis. The device allows neurologists and general practitioners to conduct a standardized oculomotor assessment in just a few minutes, generating a quantitative report that is directly comparable across time. What was once a clinical evaluation dependent on the subjective experience of the examining physician becomes an objective, trackable data point — one that is equally valuable for early diagnosis, for monitoring disease progression, and for assessing how well a patient is responding to treatment. With a total of €25 million raised — including a €10 million Series A — neuroClues is now in the commercial expansion phase across the European market, building relationships with both specialist neurology hospitals and broader networks of specialist medicine. The timing is favorable: healthcare systems across the continent are under intense pressure to deliver earlier diagnoses and more efficient clinical pathways, creating genuine demand for objective, scalable diagnostic tools that can reduce reporting times and shorten waiting lists in neurology departments. The fundamental insight behind neuroClues is that a relatively simple, non-invasive test — watching how a patient's eyes move — can unlock clinical information that currently requires far more expensive, time-consuming, and burdensome procedures to obtain. If that promise holds at commercial scale, the device could become a routine first step in the neurological workup, bringing earlier intervention within reach for far more patients.